Administering complex biologics at home via on-body devices can bridge significant healthcare disparities. This model can eliminate the physical, financial, and geographic barriers faced by patients in rural areas or those reliant on caregivers for transport to infusion centers.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

The reimbursement of weight loss drugs because they prevent future disease has set a critical precedent. This shift validates a commercial model for aging-focused therapies that aim to preemptively delay disease onset, rather than only treating established conditions, changing the calculus for the entire field.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

Avenco's NKEV therapy is designed for nasal spray delivery, avoiding hospitalization. The vesicles can be freeze-dried, shipped at room temperature, and reconstituted at home. This dramatically simplifies logistics and improves user-friendliness compared to complex, cryopreserved cell therapies, representing a major leap in manufacturability and patient access.

Eli Lilly ran the fastest-accrued Alzheimer's study in history by going direct-to-patient. This model, using televisits and centralized diagnostics, is highly effective for preventative medicines where motivated patients can be recruited online.

New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.

The shift from continuous 28-day IV infusions to subcutaneous injections represents a monumental improvement in patient quality of life. It frees patients from being tethered to a pump and managing a PICC line, which complicates daily activities like showering and introduces risks like pump failure, significantly reducing the treatment burden.

Current healthcare spending, or "Aging 1.0," focuses on managing age-related decline via retirement homes and late-stage care. The new paradigm, "Aging 2.0," uses biotechnology to prevent the need for this maintenance in the first place, representing a fundamental strategic shift.